Literature DB >> 1361306

Growth fraction in non-small cell lung cancer estimated by proliferating cell nuclear antigen and comparison with Ki-67 labeling and DNA flow cytometry data.

G Fontanini1, R Pingitore, D Bigini, S Vignati, S Pepe, A Ruggiero, P Macchiarini.   

Abstract

Results generated by the immunohistochemical staining with PC10, a new monoclonal antibody recognizing PCNA (a nuclear protein associated with cell proliferation) in formalin-fixed and paraffin-embedded tissue were compared with those of Ki-67 labeling and DNA flow cytometry in 47 consecutive non-small cell lung cancer (NSCLC). PCNA reactivity was observed in all samples and confined to the nuclei of cancer cells. Its frequency ranged from 0 to 80% (37.7 +/- 23.6) and larger sized, early-staged and DNA aneuploid tumors expressed a significant higher number of PCNA-reactive cells. The PCNA and Ki-67 labeling rates were closely correlated (r = 0.383, P = 0.009). By flow cytometry, we observed a good correlation among PCNA labeling and S-phase fraction (r = 0.422, P = .0093) and G1 phase (r = 0.303, P = .051) of the cell cycle. Results indicate that PCNA labeling with PC10 is a simple method for assessing the proliferative activity in formalin-fixed, paraffin-embedded tissue of NSCLC and correlates well with Ki-67 labeling and S-phase fraction of the cell cycle.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1361306      PMCID: PMC1886777     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  28 in total

1.  Growth fraction in lung tumours determined by Ki67 immunostaining and comparison with AgNOR scores.

Authors:  I N Soomro; W F Whimster
Journal:  J Pathol       Date:  1990-11       Impact factor: 7.996

Review 2.  Review: assessment of cell proliferation in histological material.

Authors:  P A Hall; D A Levison
Journal:  J Clin Pathol       Date:  1990-03       Impact factor: 3.411

3.  Growth fraction estimation of malignant lymphomas in formalin-fixed paraffin-embedded tissue using anti-PCNA/Cyclin 19A2. Correlation with Ki-67 labeling.

Authors:  O W Kamel; D P LeBrun; R E Davis; G J Berry; R A Warnke
Journal:  Am J Pathol       Date:  1991-06       Impact factor: 4.307

4.  Thymidine labelling index as prognostic factor in resected non-small cell lung cancer.

Authors:  A Alama; M Costantini; L Repetto; P F Conte; J Serrano; A Nicolin; F Barbieri; A Ardizzoni; P Bruzzi
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

5.  In situ evaluation of growth fraction determined by monoclonal antibody Ki-67 and ploidy in surgically resected non-small cell lung cancers.

Authors:  J Simony; J L Pujol; M Radal; E Ursule; F B Michel; H Pujol
Journal:  Cancer Res       Date:  1990-07-15       Impact factor: 12.701

6.  The expression of proliferating cell nuclear antigen in paraffin sections of peripheral, node-negative non-small cell lung cancer.

Authors:  G Fontanini; P Macchiarini; S Pepe; A Ruggiero; M Hardin; D Bigini; S Vignati; R Pingitore; C A Angeletti
Journal:  Cancer       Date:  1992-09-15       Impact factor: 6.860

7.  Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms.

Authors:  P A Hall; D A Levison; A L Woods; C C Yu; D B Kellock; J A Watkins; D M Barnes; C E Gillett; R Camplejohn; R Dover
Journal:  J Pathol       Date:  1990-12       Impact factor: 7.996

8.  Five-year follow-up study of independent clinical and flow cytometric prognostic factors for the survival of patients with non-small cell lung carcinoma.

Authors:  M Volm; E W Hahn; J Mattern; T Müller; I Vogt-Moykopf; E Weber
Journal:  Cancer Res       Date:  1988-05-15       Impact factor: 12.701

9.  Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form.

Authors:  N H Waseem; D P Lane
Journal:  J Cell Sci       Date:  1990-05       Impact factor: 5.285

10.  A search for differential polypeptide synthesis throughout the cell cycle of HeLa cells.

Authors:  R Bravo; J E Celis
Journal:  J Cell Biol       Date:  1980-03       Impact factor: 10.539

View more
  6 in total

1.  Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy.

Authors:  Günter Oberdörster; Andrew Maynard; Ken Donaldson; Vincent Castranova; Julie Fitzpatrick; Kevin Ausman; Janet Carter; Barbara Karn; Wolfgang Kreyling; David Lai; Stephen Olin; Nancy Monteiro-Riviere; David Warheit; Hong Yang
Journal:  Part Fibre Toxicol       Date:  2005-10-06       Impact factor: 9.400

2.  PRE-CLINICAL AND CLINICAL VALIDATION OF AN ANTI-CANCER MODALITY THAT ABLATES REFRACTORY, LOW GROWTH FRACTION TUMORS.

Authors:  Eric J Sorscher; Jeong S Hong; William B Parker
Journal:  Trans Am Clin Climatol Assoc       Date:  2016

3.  DNA index, cellular proliferative activity and nucleolar organizer regions in cancers of the larynx.

Authors:  J Cappiello; P Nicolai; A R Antonelli; F Facchetti; M Cadei; A Cornacchiari; P G Grigolato
Journal:  Eur Arch Otorhinolaryngol       Date:  1995       Impact factor: 2.503

4.  Role of p27Kip1 and cyclin-dependent kinase 2 in the proliferation of non-small cell lung cancer.

Authors:  H Kawana; J Tamaru; T Tanaka; A Hirai; Y Saito; M Kitagawa; A Mikata; K Harigaya; T Kuriyama
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

5.  Proliferative potential and p53 overexpression in precursor and early stage lesions of bronchioloalveolar lung carcinoma.

Authors:  H Kitamura; Y Kameda; N Nakamura; Y Nakatani; Y Inayama; M Iida; K Noda; N Ogawa; T Shibagaki; M Kanisawa
Journal:  Am J Pathol       Date:  1995-04       Impact factor: 4.307

6.  Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer.

Authors:  G Fontanini; S Vignati; D Bigini; A Mussi; M Lucchi; C A Angeletti; F Basolo; G Bevilacqua
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.